Flutamide 250 mg Tablets - Uses, Dose, Side effects, Brands

Flutamide is available as 250 mg tablets. It is an anti-androgen that inhibits the action of testosterone. It is primarily used in the treatment of prostate cancer. As an anti-androgen, it has also been used in the treatment of acne and excessive hair growth in women.

 

Indications of Flutamide:

  • Prostate carcinoma:

    • It is indicated for the management of locally confined Stage B to C and Stage D metastatic prostate cancer (in combination with a luteinizing hormone-releasing hormone [LHRH] agonist).
    • For Stage B to C prostate cancer, flutamide treatment (and goserelin) should start 8 weeks before starting radiation therapy and continue during radiation therapy.
    • For maximum treatment benefit in Stage D metastatic prostate cancer, flutamide therapy should be started with the LHRH agonist and continued until disease progression.

Bicalutamide (Casodex) is another anti-androgen used in the treatment of prostate cancer.

Flutamide dose in adults:

Flutamide dose in the treatment of metastatic prostate cancer:

  • 250 mg per oral three times a day (every 8 hours).

Use in Children:

Not indicated.

Pregnancy Risk Factor D

 

  • Studies on animal reproduction revealed negative outcomes.
  • Therapy can cause fetal harm during pregnancy.
  • It is not recommended for use by women.

Flutamide use during breastfeeding:

  • According to the manufacturer, it is not recommended for use by women.
  • It is not possible to find information about its use by breastfeeding mothers.

Dose adjustment in renal disease:

No dosage adjustment is necessary for patients with chronic renal insufficiency.

Flutamide Dose adjustment in liver disease:

  • Mild to moderate impairment:

    • There are no dosage adjustments provided in the manufacturer’s labeling.
  • Severe impairment:

    • Use is contraindicated.

Common Side Effects of Flutamide:

  • Endocrine & Metabolic:

    • Hot Flash
    • Galactorrhea
    • Decreased Libido
    • Increased Lactate Dehydrogenase
  • Gastrointestinal:

    • Diarrhea
    • Vomiting
  • Genitourinary:

    • Impotence
    • Cystitis
    • Breast Tenderness
  • Hematologic & Oncologic:

    • Rectal Hemorrhage
    • Tumor Flare
  • Hepatic:

    • Increased Serum AST

Rare Side Effects Of Flutamide:

  • Cardiovascular:

    • Edema
    • Hypertension
  • Central Nervous System:

    • Anxiety
    • Confusion
    • Depression
    • Dizziness
    • Drowsiness
    • Headache
    • Insomnia
    • Nervousness
  • Dermatologic:

    • Skin Rash
    • Ecchymoses
    • Pruritus
  • Endocrine & Metabolic:

    • Gynecomastia
  • Gastrointestinal:

    • Nausea
    • Proctitis
    • Gastric Distress
    • Anorexia
    • Constipation
    • Dyspepsia
    • Increased Appetite
  • Genitourinary:

    • Hematuria
  • Hematologic & Oncologic:

    • Anemia
    • Leukopenia
    • Thrombocytopenia
  • Infection:

    • Herpes Zoster
  • Neuromuscular & Skeletal:

    • Weakness

Contraindications to Flutamide:

Hypersensitivity to any drug or component of the formulation Severe liver dysfunction (evaluate baseline enzymes before treatment).

Warnings and precautions

  • Gynecomastia

    • Males can experience gynecomastia by using flutamide therapy with medical castration.
  • Hepatic failure: [U.S. Boxed Warning]:

    • Flutamide therapy can cause transaminitis and hepatic-encephalopathy, as well as jaundice and transaminitis.
    • Flutamide therapy is 50% effective in reducing hepatotoxicity within the first three months. In some cases, stopping the therapy can reverse hepatotoxicity.
    • Monitoring serum transaminase levels at baseline should be done monthly for four months and then periodically thereafter.
    • Liver function tests should be performed if you have symptoms such as nausea, vomiting, stomach pain, fatigue, anorexia or "flu-like", jaundice, right upper quadrant tenderness and raised bilirubin. This is consistent with hepatic dysfunction.
    • Therapy should be stopped for patients with ALT values exceeding 2x the upper normal limit.
    • Therapy should be stopped immediately if ALT is above 2x the upper normal limit.
    • Hospitalization for liver dysfunction can lead to death, but it is not common.
    • Therapy is not recommended for patients suffering from severe hepatic impairment.
  • Cardiovascular disease

    • Therapy with androgen deprivation increases the risk of cardiovascular disease.
  • Hemoglobin M Disease:

    • Patients with hemoglobin M disorder have a significantly higher risk of developing toxicities from aniline exposure.
    • Therefore, it is important to monitor methemoglobin levels closely.

Flutamide: Drug Interaction

Risk Factor C (Monitor therapy)

Abiraterone Acetate

May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).

Broccoli

May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).

Cannabis

May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).

Choline C 11

Antiandrogens may diminish the therapeutic effect of Choline C 11.

CYP1A2 Inducers (Moderate)

May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).

CYP1A2 Inhibitors (Moderate)

May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).

Cyproterone

May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).

Dapsone (Topical)

May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.

Deferasirox

May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).

Local Anesthetics

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.

Nitric Oxide

May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine.

Obeticholic Acid

May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).

Peginterferon Alfa-2b

May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).

Prilocaine

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents.

Sodium Nitrite

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia.

Teriflunomide

May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).

Risk Factor D (Consider therapy modification)

CYP1A2 Inhibitors (Strong)

May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).

Vemurafenib

May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index. Drugs listed as exceptions to this monograph are discussed in separate drug interaction monographs.

Risk Factor X (Avoid combination)

Indium 111 Capromab Pendetide

Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide.

 

Monitoring parameters:

  • PSA (prostate-specific antigen LFTs monitoring in case of symptoms including nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, hyperbilirubinemia, jaundice, or right upper quadrant tenderness. Serum transaminases (at baseline, monthly for 4 months, and periodically thereafter).

How to administer Flutamide?

It can be taken orally with or without food. It should be given in three divided doses.

Mechanism of action of Flutamide:

Nonsteroidal antiandrogen, it works by blocking androgen uptake in the target tissues and/or inhibiting androgen binding.

Absorption: Oral:

  • Rapid and complete.

Protein binding:

  • Parent drug: 94% to 96%; 2-hydroxyflutamide: 92% to 94%.

Metabolism:

  • Extensively hepatic to ≥6 metabolites, primarily 2-hydroxyflutamide (active).

Half-life elimination:

  • 6 hours (2-hydroxyflutamide).

Time to peak:

  • 2 hours (2-hydroxyflutamide).

Excretion:

  • Primarily urine (as metabolites);
  • feces (~4%).

International Brands of Flutamide:

  • DOM-Flutamide
  • Euflex
  • NU-Flutamide
  • PMS-Flutamide
  • TEVA-Flutamide
  • Androxine
  • Bedozane
  • Curestat
  • Cytomid
  • Cytomid-250
  • Drogenil
  • Etaconil
  • Eulexin
  • Eulexine
  • Eumide
  • Flucinom
  • Flucinome
  • Flugerel
  • Fluken
  • Flulem
  • Flumid
  • Fluta-Cell
  • Flutacan
  • Flutafarm
  • Flutam
  • Flutamex
  • Flutamid
  • Flutamid Abbott
  • Flutamin
  • Flutan
  • Flutanon
  • Flutaplex
  • Flutasin
  • Flutax
  • Flutexine
  • Flutrax
  • Fluxus
  • Fugerel
  • Fuprostatel
  • Grisetin
  • Profamid
  • Proscant
  • Prostacur
  • Prostalex
  • Prostica
  • Tafenil

Flutamide brands in Pakistan:

Flutamide Tablets 250 mg

Elbat Rotex Medica, Germany
Flutamida Gador Seignior Pharma
Fluten Pharmedic (Pvt) Ltd.